NCIG Announces Expiration and Results of Cash Tender Offer for Any and All of its Outstanding 4.400% Guaranteed Senior Secured Notes due 2027

NEWCASTLE, Australia, Sept. 23, 2026 /PRNewswire/ -- Newcastle Coal Infrastructure Group Pty Ltd (the "Company"), a direct wholly-owned subsidiary of NCIG Holdings Pty Ltd (the "Parent Guarantor"), announced today the expiration and results of its previously announced cash tender offer (the "Offer") for any and all of its outstanding 4.400% Guaranteed Senior Secured Notes due 2027 (the "Securities").

Expiration and Results

The Offer was made pursuant to the Offer to Purchase dated September 8, 2026 (the "Offer to Purchase") which sets forth a more detailed description of the Offer. The Offer expired at 5:00 p.m., New York City time, on September 23, 2026 (the "Expiration Date"). Withdrawal rights for the Securities expired at 5:00 p.m., New York City time, on September 23, 2026.

According to information provided by Global Bondholder Services Corporation, the tender and information agent for the Offer (the "Tender and Information Agent"), the aggregate principal amount of the Securities set forth in the table below under "Original Aggregate Principal Amount Tendered" had been validly tendered and not validly withdrawn in the Offer as of the Expiration Date.

The Company expects to accept for purchase all of the Securities validly tendered and not validly withdrawn at or prior to the Expiration Date. The Company urges the registered holders of the Securities (together, the "Holders" and each, a "Holder") to read the Offer to Purchase carefully before making any decision with respect to the Offer. The Offer to Purchase may be obtained by contacting the Tender and Information Agent using the telephone number or email address found below under "Dealer Managers and Tender and Information Agent."

Consideration and Accrued Interest

As previously announced, the Tender Offer Consideration (as defined in the Offer to Purchase) per original US$1,000 principal amount of Securities validly tendered and accepted for purchase is US$993.11, as determined at 3:00 p.m., New York City time, on September 23, 2026. The Settlement Date is expected to be September 28, 2026. In addition to the Total Consideration (as defined in the Offer to Purchase, being an amount equal to the product of (i) the original principal amount of such tendered and accepted Securities, times (ii) the Factor, times (iii) the Tender Offer Consideration), Holders whose Securities are accepted for purchase in the Offer will receive accrued and unpaid interest, rounded to the nearest cent, on the original US$1,000 principal amount of such Securities, from the last interest payment date up to, but not including, the Settlement Date.

Settlement

The Company anticipates that the Settlement Date for Securities validly tendered and not validly withdrawn at or prior to the Expiration Date and accepted for purchase will be September 28, 2026, the third business day after the Expiration Date. The Company's obligation to accept for purchase and to pay for the Securities validly tendered and not validly withdrawn at or prior to the Expiration Date in the Offer is subject to the satisfaction or waiver of a number of conditions described in the Offer to Purchase, including the Financing Condition and the General Conditions (each as defined in the Offer to Purchase). The Company reserves the absolute right, subject to applicable law, to: (i) waive any and all conditions to the Offer; (ii) extend or terminate the Offer; or (iii) otherwise amend the Offer in any respect. If the Offer is terminated at any time, the Securities tendered pursuant to the Offer will be promptly returned to the tendering Holders.

Dealer Managers and Tender and Information Agent

Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC are acting as the dealer managers for the Offer (together, the "Dealer Managers"). The Tender and Information Agent for the Offer is Global Bondholder Services Corporation. For additional information regarding the terms of the Offer, please contact: Citigroup Global Markets Inc. at +1 (212) 723-6106 (collect) or +1 (800) 558-3745 (toll-free) or by email at ny.liabilitymanagement@citi.com, or Goldman Sachs & Co. LLC at +1 (212) 343-9668 (collect) or +1 (800) 828-3182 (toll-free) or by emailing at [email protected]. Requests for documents and questions regarding the tendering of Securities may be directed to Global Bondholder Services Corporation by telephone at (212) 430‐3774 (for banks and brokers only), (855) 654‐2015 (toll‐free) or 001‐212‐430‐3774 (international) or by email at contact@gbsc‐usa.com.

This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell with respect to any securities. The Offer is being made pursuant to the Offer to Purchase and only in such jurisdictions as is permitted under applicable law. The Offer is not being made in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

None of the Company, the Parent Guarantor, their respective affiliates, their respective boards of directors, the Dealer Managers, the Tender and Information Agent or the trustee for the Securities is making any recommendation as to whether Holders should tender any of their Securities in connection with the Offer. Holders must make their own decision as to whether to tender any of their Securities, and, if so, the original principal amount of Securities to tender. Holders should consult their own tax, accounting, financial and legal advisers as they deem appropriate regarding the suitability of the tax, accounting, financial and legal consequences of participating or declining to participate in the Offer.

About the Company

The Company owns and operates a Coal Export Terminal located at the Port of Newcastle in the Hunter Valley region of New South Wales in Australia and is an integral part of the Australian coal export industry. The Company's facilities include rail, coal storage, ship loading facilities and associated infrastructure. The Company was formed in 2004 by its shareholders who are also customers of the Company's Terminal services. The shareholders of the Company are entities that are owned by some of the largest mining companies in the world, including BHP Group Limited, Yancoal Australia Limited, Whitehaven Coal Mining Limited, Peabody Energy Corporation, Banpu Public Company Limited (Centennial Coal) and Malabar Resources Limited, who each owns coal assets in New South Wales, Australia.

Forward-Looking Statements

This release contains forward‐looking statements. Forward‐looking statements are information of a non‐historical nature or which relate to future events and are subject to risks and uncertainties, such as the timing and results of, and other expectations regarding, the Financing Condition and the Offer. No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such transactions. You should not place undue reliance on these forward‐looking statements. Except as required by law or regulation, the Company does not undertake any obligation to update these forward‐looking statements.

SOURCE Newcastle Coal Infrastructure Group Pty Ltd

Share this article

Across Meta AI glasses, Instagram, and VR devices, Dolby Atmos and Dolby Vision bring greater depth, authenticity, and emotion to the experiences that matter most

SAN FRANCISCO and MENLO PARK, Calif., Sept. 23, 2026 /PRNewswire/ -- Today, Dolby Laboratories (NYSE: DLB) and Meta (NASDAQ: META) announced the expansion of Dolby experiences within the Meta ecosystem of devices and platforms. This includes new Dolby experiences coming to Meta AI glasses and Instagram.

Announced today at Meta Connect, Meta AI glasses are the first global consumer device capable of capturing audio in Dolby Atmos. Users can capture their favorite moments and share them on Instagram with their community, helping them relive those experiences and feel closer to what made them special. The news builds on the launch of Dolby Vision on Instagram last year.

"Today, creating and sharing content is part of everyday life," said John Couling, Senior Vice President of Entertainment, Dolby Laboratories. "As the lines between entertainment, creation, and social sharing get closer, people want experiences that feel more emotionally engaging. Together with Meta, we're bringing Dolby Atmos and Dolby Vision to more of the experiences people enjoy every day, making them more authentic and true to life."

Meta also announced today that its newest VR device will support Dolby Vision and Dolby Atmos, enabling more immersive experiences for movies, shows, sports, concerts, and other premium VR experiences when it launches next year.

Today's announcement reflects a broader shift in how people watch, create, and share their stories. The same technologies trusted by filmmakers, artists, and storytellers are increasingly becoming part of everyday consumption and self-expression. With Dolby, people can create, experience, and share moments in ways that feel more authentic and emotionally engaging.

The expansion also broadens Dolby's presence across one of the world's largest ecosystems for entertainment, creation, and social sharing, bringing Dolby experiences to more of the ways people connect, create, and engage every day.

Together, Dolby Atmos and Dolby Vision help people feel closer to the stories, experiences, and moments that matter most.

About Dolby:

Dolby Laboratories (NYSE: DLB) is a world leader in immersive entertainment. From movies and TV, to music, sports, gaming, and beyond, Dolby transforms the science of sight and sound into spectacular experiences for billions of people worldwide across all their favorite devices. We partner with artists, storytellers, and the brands you love to transform entertainment and digital experiences through groundbreaking innovations like Dolby Atmos, Dolby Vision, Dolby Cinema, and Dolby OptiView.

Dolby, Dolby Vision, Dolby Atmos, Dolby Cinema, Dolby OptiView and the double-D symbol are trademarks or registered trademarks of Dolby Laboratories Licensing Corporation in the United States and/or other countries. Other trademarks are the property of their respective owners.

Media Contacts:

Dolby

Cairon "Jamie" Armstrong

[email protected]

Kaitlyn Kazan

[email protected]

SOURCE Dolby Laboratories, Inc.

Share this article

- Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC -

- Milestone marks second Phase 3 study of setidegrasib initiated within six months -

TOKYO, Sept. 23, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-targeted protein degrader, versus docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on or after initial platinum-based chemotherapy and checkpoint inhibitor therapy (CPI).1

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death worldwide, with NSCLC accounting for approximately 80% of cases.2,3 Around 5% of people with NSCLC have a KRAS G12D mutation.4 Despite advances in targeted treatment for other molecularly defined forms of NSCLC, there are currently no therapies approved specifically for people with KRAS G12D-mutated NSCLC.3,5 Patients whose disease progresses on or after initial treatment currently rely on standard systemic options, such as chemotherapy.5

Setidegrasib is an investigational targeted protein degrader designed to degrade and eliminate the disease-driving KRAS G12D protein. By removing this protein, setidegrasib may help disrupt cancer cell signaling and destroy cancer cells.4 This Phase 3 study in previously treated NSCLC builds on early clinical evidence published in The New England Journal of Medicine in March 2026, which demonstrated antitumor activity and a manageable safety profile in patients with KRAS G12D-mutated solid tumors, supporting the proposed mechanism of action of setidegrasib.4

Hidenori Kitai, M.D., Ph.D., Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Japan:

"For too long, patients with KRAS G12D-mutated non-small cell lung cancer have had limited treatment options after standard therapies. This Phase 3 study represents an important step forward for the field, helping to build the evidence needed to understand whether setidegrasib could offer a potential new approach for this molecularly defined patient population."

Tadaaki Taniguchi, M.D., Ph.D., Chief Research and Development Officer, Astellas:

"The initiation of this Phase 3 study in NSCLC, our second Phase 3 study of setidegrasib within six months, reflects continued progress in its clinical development. This study will help us understand how setidegrasib's novel approach to degrading disease-driving KRAS G12D may help address unmet needs for patients with this type of NSCLC. We are grateful to the patients, investigators and study teams making this research possible."

Setidegrasib is Astellas' lead investigational targeted protein degrader. Initiation of the Phase 3 study in previously treated patients with NSCLC supports Astellas' Corporate Strategic Plan, with an ambition to initiate five or more Phase 3 or pivotal studies by fiscal year 2027. It follows the initiation of a Phase 3 study of setidegrasib in front-line pancreatic ductal adenocarcinoma (PDAC) in April 2026.6

To further inform the scientific understanding of setidegrasib and KRAS G12D-driven disease biology, Astellas will also present translational analyses from the Phase 1 study of setidegrasib in patients with KRAS G12D-mutated PDAC at the upcoming AACR Conference on Pancreatic Cancer, September 25–28, 2026.7,8 The analyses will provide further insight into mechanisms of response, resistance and potential rational combination approaches in pancreatic cancer. The findings will be featured in both a proffered oral presentation and a poster presentation.*

* Presentation details at AACR Conference on Pancreatic Cancer

Title: Integrated translational analyses of the first-generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offer rational combination strategies

Lead author: Wungki Park, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center

Details: Poster Presentation: Poster Number: B040, Date: September 27, 2026, 5:00–7:00 p.m. PT; Oral Presentation (short talk from proffered abstract): Abstract Number: PR014 B040, Date: September 28, 2026, 9:42 a.m. PT.

About the Phase 3 NSCLC Study1

The randomized, open-label Phase 3 study is evaluating setidegrasib compared with docetaxel in people with KRAS G12D-mutated locally advanced (unresectable) or metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy (CPI). The dual primary endpoints are progression-free survival (PFS), assessed by blinded independent central review, and overall survival (OS). Astellas plans to enroll approximately 356 patients across multiple countries into the study.

About setidegrasib4,9,10  

Setidegrasib is a novel, investigational targeted protein degrader designed to degrade and eliminate the disease-driving KRAS G12D protein. By removing this protein, setidegrasib may help disrupt cancer cell signaling and destroy cancer cells. Discovered and advanced through Astellas' in-house R&D capabilities, setidegrasib is designed to work with the cancer cell's own protein degradation machinery to bring together the KRAS G12D protein and an E3 ligase. This triggers selective degradation of the disease-driving protein, providing a distinct approach to targeting this cancer-driving mutation.

For more information on the Phase 3 study of setidegrasib in previously treated NSCLC, visit ClinicalTrials.gov and search for identifier NCT07566052. For more information about the Phase 3 study of setidegrasib in front-line PDAC, visit ClinicalTrials.gov and search for identifier NCT07409272.

The safety and efficacy of setidegrasib have not been established for the uses being considered. There is no guarantee that setidegrasib will receive regulatory approval and become commercially available for the uses being investigated.

About Astellas' Corporate Strategic Plan

Learn more at www.astellas.com/en/about/corporate-strategic-plan.

About Astellas

Astellas is a global life sciences company committed to turning innovative science into value for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions, and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

References

- ClinicalTrials.gov. U.S. National Library of Medicine. A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation. Identifier: NCT07566052. Available at: https://clinicaltrials.gov/study/NCT07566052. Last accessed September 21, 2026.

- World Health Organization. 2026. Lung cancer. Available at: https://www.who.int/news-room/fact-sheets/detail/lung-cancer. Last accessed September 21, 2026.

- Tang Y, et al. Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential. Cancer Gene Ther. 2024;31(7):961-969. doi:10.1038/s41417-024-00778-4.

- Park W, et al. Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer. N Engl J Med. 2026;394(14):1409-1420. doi:10.1056/NEJMoa2600752.

- Reuss et al. Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO Living Guideline. J Clin Oncol. 2026;44(7):e56-e88. doi:10.1200/JCO-25-02825.

- ClinicalTrials.gov. U.S. National Library of Medicine. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer. Identifier: NCT07409272. Available at: https://clinicaltrials.gov/study/NCT07409272. Last accessed September 21, 2026.

- Park W. Integrated translational analyses of the first-generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offer rational combination strategies. Oral presentation at: AACR Conference on Pancreatic Cancer; September 25–28, 2026; San Diego, CA.

- Park W, et al. Integrated translational analyses of the first-generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offer rational combination strategies. Poster presented at: AACR Conference on Pancreatic Cancer; September 25–28, 2026; San Diego, CA.

- Yoshinari T, et al. Discovery of KRAS(G12D) selective degrader ASP3082. Commun Chem. 2025;8:254.

- Paz-Ares L, et al.

ANAHEIM, Calif., Sept. 23, 2026 /PRNewswire/ -- Credit Union of Southern California (CU SoCal) recently donated more than $340,000 to nonprofit organizations, educational programs, youth development initiatives, and community services across Southern California. Distributed throughout the summer, the contributions supported organizations serving Los Angeles, Orange, Riverside, and San Bernardino counties.

The donations supported a wide range of community-driven efforts focused on education, youth development, wellness, and essential services, including:

- $35,000 for Soroptimist International of Whittier and the Whittier Host Lions Club.

- $34,000 for families served by Ronald McDonald House Pasadena.

- $25,000 in combined support for Interfaith Food Center and the Welcome Home Project at Whittier Community Church.

Additional contributions supported local schools, youth organizations, educational and scholarship programs, community wellness efforts, and services for individuals and families throughout the region.

"These donations reflect CU SoCal's ongoing commitment to the communities we serve," said Dave Gunderson, President and CEO of CU SoCal. "By partnering with organizations that provide essential services and opportunities, we can extend our impact beyond financial services and help create stronger communities."

Through charitable giving, sponsorships, volunteerism, and community partnerships, CU SoCal invests in initiatives that expand opportunity and improve quality of life across Southern California.

About Credit Union of Southern California (CU SoCal)

Founded in 1954 as Whittier Area Schools Federal Credit Union, Credit Union of Southern California (CU SoCal) is a federally chartered credit union open to anyone who qualifies for Membership. Individuals may become Members through family or household relationships, employer partnerships, select educational institutions, residency or employment in Lake Havasu City, Arizona, or through a complimentary membership in a CU SoCal nonprofit partner association. CU SoCal remains a Member-owned, not-for-profit cooperative dedicated to helping Members build better lives through personalized financial services and support. CU SoCal has a superior five-star financial rating from BauerFinancial, holds more than $4 billion in assets, and serves more than 187,000 Members. For more information, visit CUSoCal.org.

SOURCE Credit Union of Southern California

Share this article

SAN FRANCISCO, Sept. 23, 2026 /PRNewswire/ -- Hagens Berman, a national law firm noted for its preeminent work in securities class action litigation, notifies investors in HDFC Bank Limited (NYSE: HDB) of a pending securities fraud class action.

- Class Period: July 17, 2023 – May 26, 2026

- Lead Plaintiff Deadline: Oct. 13, 2026

- Visit: www.hbsslaw.com/hdb

- Contact the Firm Now: [email protected] / 844-916-0895

HDFC Bank Limited (HDB) Securities Class Action Overview:

The lawsuit filed against HDFC Bank Limited ("HDFC" or the "Company"), and certain top executive officers including Chief Executive Officer Sashidhar Jagdishan and Chief Financial Officer Srinivasan Vaidyanathan, alleges violations of the federal securities laws.

Specifically, the action centers on HDFC's failure to disclose key material adverse facts regarding its business operations, financial accounting, and regulatory compliance:

- Camouflaged Marketing Payments & Covert Deposit Inducements: HDFC secretly funneled approximately Rs 45 crore (approx. $4.7 million USD) to the Maharashtra State Road Development Corporation ("MSRDC") to induce the state firm to place large deposits with the bank.

- Disguised Above-Market Interest Rates: To circumvent regulations and provide MSRDC with a 6.01% interest rate (a 2.51% markup over standard retail savings accounts), senior management devised a scheme to route the differential payments through the marketing department disguised as sponsorship contributions for a road safety awareness campaign.

- Governance and Regulatory Breaches: These covert practices violated the Reserve Bank of India's (RBI) Master Directions on interest rates and breached the bank's own internal anti-bribery and anti-corruption policies prohibiting improper inducements.

- Overstated Financials: As a result of these hidden activities, HDFC's interest income and operating expenses were overstated during the class period, rendering the Company's positive public statements and financial controls false and misleading.

Truth Begins to Unravel & Stock Price Declines:

The fraudulent scheme allegedly began to surface in stages, causing sharp drops in the market value of HDFC American Depositary Shares (ADS):

- March 18, 2026: HDFC announced the abrupt resignation of part-time Chairman and Independent Director Atanu Chakraborty, whose resignation letter stated that happenings and practices within the bank over the prior two years were "not in congruence with my personal Values and Ethics." On this news, HDFC ADS prices fell 7.28% on heavy volume.

- May 27, 2026: The Indian Express published an investigative report exposing that HDFC "camouflaged crores as marketing spend" to pay higher interest to MSRDC, revealing an internal vigilance probe implicating CEO Sashidhar Jagdishan and other top leadership. Following this disclosure, HDFC ADS fell 4.1% to close at $23.78 per share.

Hagens Berman's Investigation

"We're focused on whether HDFC's senior leadership concealed a covert scheme to funnel millions in disguised payments to induce state-firm deposits while publicly painting a picture of strong governance and compliance, as the complaint alleges," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.

What Affected $HDB Investors Should Do

If you purchased or acquired HDFC securities between July 17, 2023, and May 26, 2026, and suffered significant financial losses, you have until October 13, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/hdb, call Reed Kathrein at 844-916-0895, or email [email protected].

Whistleblowers: Persons with non-public information regarding HDFC should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

Built inside a working stone shop, it is the first product of the Fabrication Cloud — homeowners to local fabricators, measured and priced before anyone visits

ST. LOUIS, Sept. 23, 2026 /PRNewswire/ -- Novaclad today released the first consumer product built on its AI-LiDAR measurement engine: a free iOS app that lets a homeowner measure their kitchen with an iPhone, price a countertop from a real catalog, and hand the job to a local fabricator in about five minutes. It is the first of its kind and the first piece of the company's Fabrication Cloud.

Custom fabrication — countertops, cabinetry, tile, millwork — is a large corner of residential construction still run on tape measures and quotes that arrive days later as one number. Novaclad's engine captures a room in three dimensions with the iPhone's LiDAR sensor, then applies a model trained on how a working shop reads a kitchen to produce a fabrication-grade takeoff and an itemized price from the shop's own price book. The fabricator receives a lead already measured and specified.

The engine was not built in a software lab. Co-founders Ryan and Audrey Brown left corporate careers in 2022 to buy Rock Creek Granite, an Imperial, Missouri, shop cutting stone since 2013 — and built Novaclad on its floor.

"We saw automation coming for the industries we came from and asked where it was needed and nobody was looking," said Ryan Brown. "Fabrication has a material-waste problem and a measurement problem. Both are software problems now."

"We didn't automate the craftsman," said Audrey Brown. "We automated the two weeks of waiting in front of him. The saw still happens. What's gone is the guesswork."

Novaclad launches in St. Louis with Rock Creek Granite as founding fabricator and places one fabricator per market through its Founder-Partner program. Countertops are the first surface; the engine is built to extend to other fabricated finishes.

The app is free; homeowners pay their fabricator for the work. It requires an iPhone 12 Pro or newer Pro model on iOS 17 or later: novaclad.com/app.

About Novaclad

Novaclad LLC is a St. Louis construction-technology company founded by Ryan and Audrey Brown, part of the Fourfold Futures venture studio. novaclad.com 

SOURCE Novaclad

Share this article

PEOPLE INCORPORATED WITHDRAWS PROPOSAL TO PURCHASE ALL PUBLIC SHARES OF MGM RESORTS INTERNATIONAL

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Today People Incorporated (NASDAQ: PPLI) announced it has withdrawn its proposal to purchase all public shares of MGM Resorts International.

People Incorporated Chairman and Senior Executive Barry Diller said, "There are lots of ingredients that go into a proposal of this kind on its way to completion. We didn't feel the mix was coming together in the way we had hoped and have decided not to pursue taking the company private at this time. What is undimmed is our belief in the future of MGM Resorts. We continue to hold 66.8 million shares representing approximately 27% of MGM Resorts and have total confidence in both the management and the Company's prospects."

Continued Mr. Diller, "I want to thank the Special Committee and all the MGM Directors for giving us the time and consideration during the process. People Incorporated is doing just fine with its principal publishing business achieving its 11th quarter of growth with plenty of cash to both invest in its business and purchase its stock."

"We at People Incorporated remain open to and interested in the possibility of a strategic transaction with MGM Resorts and look forward to considering a range of alternatives," concluded Mr. Diller.

Cautionary Statement Regarding Forward-Looking Information

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as "anticipates," "intends," "estimates," "expects," "plans" and "believes," among others, generally identify forward-looking statements. These forward-looking statements include, among others, statements relating to future investments in our business and purchase of our stock, and the possibility of a strategic transaction. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others: (i) the impact of advances in artificial intelligence ("AI") and other digital technologies, including AI-enabled search features, on how users access and consume information and the resulting effects on traffic, engagement and monetization, (ii) our reliance on search engines and third-party platforms, including changes in algorithms, policies, economics or features (including those implemented by Google), as well as the potential expiration or modification of key commercial agreements, (iii) our ability to effectively market our products and services in a cost-efficient manner across evolving digital channels, (iv) our dependence on advertising revenue and the sensitivity of such revenue to macroeconomic conditions, including factors affecting advertiser demand, consumer confidence and discretionary spending, as well as geopolitical and broader market uncertainty, (v) our ability to adapt to changes in digital marketing practices, including limitations on data access, tracking technologies and targeting capabilities, (vi) our ability to develop, distribute and monetize our products and services across mobile and other platforms and maintain effective relationships with third-party partners, (vii) the continued growth, engagement and monetization of our digital publishing brands, (viii) risks related to our Print business, including ongoing revenue declines, cost pressures (including paper and postage), and reliance on key vendors, (ix) our ability to access, collect, use and protect personal data and comply with evolving privacy and data protection laws and platform restrictions, (x) our ability to effectively engage with users, subscribers and caregivers across communication channels, (xi) the concentration of voting control among our Chairman and Senior Executive and related parties, (xii) risks related to our liquidity and indebtedness, including our ability to service debt and comply with related covenants, as well as limitations on access to subsidiary cash flows, (xiii) risks related to strategic transactions and initiatives, including our ability to realize anticipated benefits from prior transactions and execute future initiatives, (xiv) competitive pressures in rapidly evolving industries, including from larger or better-positioned competitors and AI-enabled offerings, (xv) our ability to build, maintain and protect our brands, (xvi) cybersecurity risks, including increasingly sophisticated attacks (including those enabled by AI) and vulnerabilities at third-party providers, (xvii) data security breaches, fraud and related liabilities, (xviii) risks associated with the integrity, scalability and reliability of our systems, technology and infrastructure, (xix) the impact of general economic, geopolitical and public health conditions, (xx) our dependence on key personnel and leadership transitions, (xxi) volatility in our stock price and risks related to our capital allocation strategy, and (xxii) risks related to the ongoing corporate consolidation. Certain of these and other risks and uncertainties are described in our filings with the Securities and Exchange Commission (the "SEC"), including the most recent Annual Report on Form 10-K filed with the SEC on February 20, 2026, and subsequent reports that we file with the SEC. Other unknown or unpredictable factors that could also adversely affect our business, financial condition and results of operations may arise from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those expressed in any forward-looking statements we may make. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

About People Incorporated

People Incorporated is the owner of America's largest publisher, People Inc., home to more than 40 celebrated brands including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living, attracting a total of 175 million consumers each month. The company also holds a significant minority stake in MGM Resorts International, reflecting our belief in the power and potential of businesses built around enduring consumer brands and iconic, real-world experiences.

People Incorporated represents the latest evolution in a long tradition of entrepreneurial ownership, disciplined capital allocation, and opportunistic value creation. Over three decades, the company has built, operated, invested in, and spun off many of the internet and media industry's defining businesses, and that same spirit of opportunism drives us today. People Incorporated is headquartered in New York City. To learn more visit https://ir.people-incorporated.com.

Contact Us

People Incorporated Investor Relations

Mark Schneider

(212) 314-7400

People Incorporated Corporate Communications

Valerie Combs

(212) 314-7251

SOURCE People Incorporated

Share this article

Company Confirms People Incorporated Has Withdrawn its Proposal to Acquire MGM Resorts

LAS VEGAS, Sept. 23, 2026 /PRNewswire/ -- MGM Resorts International (NYSE: MGM) ("MGM Resorts" or the "Company") confirms that People Incorporated ("People") has withdrawn its June 1, 2026, proposal to acquire all of the outstanding shares of the Company that it does not already own. Over the past several months, a special committee of MGM Resorts' Board has participated in negotiations with People to advance the interests of its shareholders. MGM Resorts will continue as a standalone company.

"The Board remains excited to continue to lead MGM Resorts as a standalone company. Our leading position in Las Vegas, our best-in-class regional properties, and BetMGM's continued momentum highlight the value we bring to our shareholders. In addition, our international portfolio of MGM China and the significant opportunity ahead with MGM Osaka support a clear path to increasing shareholder value," said Paul Salem, Chairman of the MGM Resorts Board.

About MGM Resorts International

MGM Resorts International (NYSE: MGM) is an S&P 500® global gaming and entertainment company with national and international destinations featuring best-in-class hotels and casinos, state-of-the-art meetings and conference spaces, incredible live and theatrical entertainment experiences, and an extensive array of restaurant, nightlife and retail offerings. MGM Resorts creates immersive, iconic experiences through its suite of Las Vegas-inspired brands. The MGM Resorts portfolio encompasses 30 unique hotel and gaming destinations globally, including some of the most recognizable resort brands in the industry. The Company's 50/50 venture, BetMGM, LLC, offers sports betting and online gaming in North America through market-leading brands, including BetMGM and partypoker, and the Company's subsidiary, LV Lion Holding Limited, offers sports betting and online gaming through market-leading brands in several jurisdictions throughout Europe and Brazil. The Company is currently pursuing targeted expansion in Asia through an integrated resort development in Japan. Through its Focused on What Matters philosophy, MGM Resorts commits to creating a more sustainable future, while striving to make a bigger difference in the lives of its employees, guests and in the communities where it operates. The global employees of MGM Resorts are proud of their company for being recognized as one of FORTUNE® Magazine's World's Most Admired Companies®. For more information, please visit us at www.mgmresorts.com. Please also connect with us @MGMResortsIntl on X as well as Facebook and Instagram.

Forward Looking Statements

Statements in this release that are not historical facts are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and involve risks and/or uncertainties, including those described in the Company's public filings with the Securities and Exchange Commission. Forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," "could," "may," "will," "should," "seeks," "likely," "intends," "plans," "projects," "estimates" or "anticipates" or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate solely to historical matters. The Company has based forward-looking statements on management's current expectations and assumptions and not on historical facts. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise, and the Company may not be able to realize them. These forward-looking statements involve a number of risks and uncertainties. Among the important factors that could cause actual results to differ materially from those indicated in such forward-looking statements include risks relating to any strategic transaction the Company may undertake and the effects of such a transaction, or the completion or failure to complete such a transaction, on the Company's business, the effects of economic conditions and market conditions in the markets in which the Company operates and competition with other destination travel locations throughout the United States and the world, the design, timing and costs of expansion projects, risks relating to international operations, permits, licenses, financings, approvals and other contingencies in connection with growth in new or existing jurisdictions, the risks in the Company's execution of its strategic plan and additional risks and uncertainties described in the Company's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports). In providing forward-looking statements, the Company is not undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise, except as required by law. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those other forward-looking statements.

MGM RESORTS CONTACTS:

Investment Community

SARAH ROGERS

Senior Vice President of Corporate Finance & Treasurer

[email protected]

HOWARD WANG

Vice President of Investor Relations

[email protected] 

News Media

BRIAN AHERN

Executive Director of Communications

[email protected] 

SOURCE MGM Resorts International

Share this article

PUNE, India, Sept. 23, 2026 /PRNewswire/ -- The Bladder Cancer Treatment Market was valued at USD 5.13 Billion in 2025 and is projected to expand at a 9.2% CAGR from 2026 to 2034, reaching USD 11.33 Billion by 2034, according to a new analysis by Maximize Market Research.

Global Bladder Cancer Treatment Market

The Global Bladder Cancer Treatment Market Report 2025 provides a comprehensive analysis of market trends, bladder cancer incidence, patient population, treatment procedures, clinical research, drug development pipeline, therapeutic innovations, technological advancements, regulatory developments, competitive landscape, treatment adoption, and market forecasts through 2034. The market covers invasive bladder cancer, non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), transitional bladder cancer, superficial bladder cancer, squamous cell bladder cancer, and other bladder cancer types across surgery, intravesical chemotherapy, systemic chemotherapy, radiation therapy, immunotherapy, and targeted therapy.

The rising incidence of bladder cancer, growing geriatric population, increasing cancer awareness, demand for early diagnosis, and expanding access to advanced oncology treatment are supporting the growth of the global bladder cancer treatment market. Increasing adoption of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), targeted therapies, intravesical therapies, precision medicine, biomarker-driven treatment, and personalized cancer treatment is transforming bladder cancer management. Growing investments in oncology research, clinical trials, pharmaceutical R&D, drug discovery, immuno-oncology, and novel therapeutic development are further expanding treatment opportunities for patients with early-stage, recurrent, advanced, and metastatic bladder cancer.

Advancements in immunotherapy, targeted cancer therapy, antibody-drug conjugates, FGFR inhibitors, intravesical drug delivery, gene therapy, liquid biopsy, molecular diagnostics, biomarker testing, robotic-assisted surgery, bladder-preserving treatment, and precision oncology are reshaping the bladder cancer treatment landscape. Increasing research into non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, urothelial carcinoma, carcinoma in situ (CIS), recurrent bladder cancer, and metastatic urothelial cancer is creating new opportunities for pharmaceutical and biotechnology companies. Product launches, FDA approvals, clinical trial advancements, strategic collaborations, licensing agreements, acquisitions, pipeline expansion, and investments in next-generation cancer therapies are expected to accelerate innovation and strengthen the global bladder cancer treatment market through 2034.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/188173/

Global Bladder Cancer Treatment Market gains momentum as rising bladder cancer incidence, growing demand for advanced cancer treatment, increasing adoption of immunotherapy and targeted therapy, advances in antibody-drug conjugates and intravesical drug delivery, and expanding precision oncology and bladder-preserving approaches accelerate therapeutic innovation: Maximize Market Research unveils key market insights.

Global Bladder Cancer Treatment Market Size & Forecast

Global Bladder Cancer Treatment Market Trends & Insights

- North America leads the Global Bladder Cancer Treatment Market, supported by advanced healthcare infrastructure, high bladder cancer incidence, strong oncology research, and major pharmaceutical companies.

- Asia-Pacific is a high-growth region, driven by rising cancer awareness, improving healthcare infrastructure, growing geriatric population, and increasing access to advanced cancer therapies.

- Immunotherapy and targeted therapies are gaining adoption, with growing use of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and FGFR inhibitors in bladder cancer treatment.

- Intravesical and bladder-preserving therapies are expanding, supported by advances in localized drug delivery, gene therapy, and innovative treatments for non-muscle-invasive bladder cancer.

- Precision oncology is driving treatment innovation, with increasing focus on biomarker testing, molecular diagnostics, personalized treatment, clinical trials, and novel drug development.

Rising Incidence of Bladder Cancer Drives Market Growth

The increasing incidence of bladder cancer, growing geriatric population, and rising awareness of cancer diagnosis are driving demand for effective treatment. Growing cases of non-muscle-invasive and muscle-invasive bladder cancer are increasing the need for surgery, chemotherapy, immunotherapy, targeted therapy, and advanced bladder cancer treatments.

High Treatment Costs Restrain Market Growth

The high cost of advanced cancer therapies, medical devices, diagnostic procedures, and prolonged treatment can limit patient access. Expensive immunotherapies, targeted therapies, and specialized treatment facilities can create affordability challenges, particularly in developing and cost-sensitive markets.

Advancements in Immunotherapy and Targeted Therapies Create Opportunities

Rapid development of immune checkpoint inhibitors, antibody-drug conjugates (ADCs), FGFR inhibitors, gene therapy, and intravesical drug delivery is creating new opportunities. Growing research in precision oncology, biomarker-based treatment, and bladder-preserving therapies is further expanding the treatment landscape.

Limited Healthcare Infrastructure and Skilled Professionals Create Challenges

Limited access to advanced cancer diagnosis, specialized treatment facilities, and trained oncology professionals remains a challenge in several developing regions. Differences in healthcare infrastructure, treatment accessibility, regulatory requirements, and availability of advanced therapies can restrict the adoption of innovative bladder cancer treatments.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/188173/

Global Bladder Cancer Treatment Market Segmentation

The Global Bladder Cancer Treatment Market is segmented by Type, Diagnosis Method, Treatment Method, Treatment Channel, and Region. Rising bladder cancer incidence, growing demand for early diagnosis, increasing adoption of immunotherapy and targeted therapies, advances in intravesical treatment, and expanding research into innovative bladder cancer therapies are supporting market development across these segments.

North America Leads the Bladder Cancer Treatment Market While Asia Pacific Emerges as a High-Growth Region

North America held the largest share of the Global Bladder Cancer Treatment Market in 2025, supported by high bladder cancer incidence, advanced healthcare infrastructure, strong oncology research, and high healthcare expenditure. The United States represents a major market due to the presence of leading pharmaceutical companies, advanced cancer treatment centers, and growing adoption of immunotherapy, targeted therapy, antibody-drug conjugates (ADCs), and precision medicine. Canada and Mexico are also contributing through improving cancer-care infrastructure and increasing access to advanced treatment.

Europe represents an important market, supported by established healthcare systems, strong pharmaceutical and biotechnology industries, and increasing investments in oncology research. Germany, the United Kingdom, France, Italy, Spain, Sweden, Switzerland, and other European countries are witnessing growing adoption of immunotherapy, targeted therapies, intravesical treatments, and personalized bladder cancer therapies. Increasing clinical research and regulatory support for innovative cancer treatments are further supporting regional development.

Asia Pacific is expected to witness strong growth as healthcare infrastructure, cancer awareness, and access to advanced oncology treatments improve. China, Japan, India, South Korea, Australia, and other regional markets are contributing to market development. Rising investments in pharmaceutical R&D, clinical trials, immuno-oncology, precision medicine, and bladder cancer research are creating new opportunities for advanced treatment adoption.

Middle East & Africa is gradually developing as healthcare infrastructure and access to specialized oncology services improve. GCC countries, South Africa, Egypt, Nigeria, and other markets are investing in advanced diagnostic and cancer treatment capabilities. Growing awareness of bladder cancer and increasing demand for modern therapies are supporting regional market development.

South America is supported by improving healthcare infrastructure, increasing cancer awareness, and expanding access to advanced treatment options. Brazil represents an important regional market, while Argentina, Chile, Colombia, Peru, and other countries are contributing through developing oncology services and growing demand for innovative bladder cancer therapies.

Leading Companies Strengthen the Bladder Cancer Treatment Landscape

Merck & Co., Inc., Pfizer Inc., Bristol Myers Squibb Company, Johnson & Johnson, UroGen Pharma Ltd., CG Oncology, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Astellas Pharma Inc., Ferring Pharmaceuticals, Kissei Pharmaceutical Co., Ltd., and ImmunityBio, Inc. are among the prominent companies associated with the global bladder cancer treatment landscape. Their activities across immunotherapy, targeted therapy, antibody-drug conjugates, intravesical drug delivery, gene therapy, and uro-oncology are supporting treatment innovation and commercialization.

Artemis Growth Partners Appoints James Hayward as Advisory Director Amid Institutional Shift in Global Emergent Medicinal Therapeutics

LONDON, Sept. 23, 2026 /PRNewswire/ -- Artemis Growth Partners ("Artemis"), a global investment firm specializing in regulated medical cannabis and emergent medicinal therapeutics, today announced the appointment of James Hayward as Advisory Director.

Mr. Hayward joins Artemis following a 35-year career at JPMorgan, where he was a central figure in building the firm's European credit distribution franchise. James founded and led JPMorgan's European hedge fund credit business and worked closely with institutional investors through multiple economic and market cycles. His experience spans leveraged finance, high yield, credit derivatives and distressed markets.

At Artemis, Mr. Hayward will work alongside co-founder and Chief Investment Officer William Muecke and Managing Partner E. Stanton McLean. He will advise the firm on capital formation, business development, LP relationships, and strategic financing initiatives across its global platform.

His appointment comes as the global medical cannabis and emergent medicinal therapeutics markets enter a more mature phase of development. Regulatory frameworks are evolving, particularly across Europe, while investors are placing greater emphasis on governance, capital discipline, operating performance, and sustainable business models.

William Muecke, Co-Founder and CIO of Artemis, said:

"James brings a rare combination of market judgment, institutional relationships and experience building credit businesses. As the medical cannabis sector matures and financing requirements become more sophisticated, his perspective will be highly valuable to Artemis and to the companies in which we invest."

E. Stanton McLean, Managing Partner of Artemis, added:

"James and I were partners at JPMorgan as the European credit markets developed into a major institutional asset class. He understands how emerging markets evolve; how capital structures need to adapt and what sophisticated investors require. Those capabilities are directly relevant to the next stage of development for the emergent medicinal therapeutics industry."

James Hayward commented:

"In taking the time to evaluate and understand the industry, I have seen both its complexity and its potential. Medical cannabis is still heavily stigmatized despite growing evidence of its efficacy and compelling patient experiences. Most institutional investors remain unaware of how rapidly the industry is developing and the opportunity taking shape. Artemis has the experience, credibility, and global platform to change that - and I am delighted to be joining the firm."

Mr. Hayward's appointment further strengthens Artemis's institutional capabilities as the firm deepens its engagement with hedge funds, family offices and private equity investors and continues to support businesses operating across regulated markets.

About Artemis Growth Partners

Artemis Growth Partners is a global investment firm specializing in regulated medical cannabis and emerging therapeutics. Founded in 2017, the firm manages more than $300 million in discretionary assets across six dedicated investment vehicles, with investments spanning North America, Europe and other international markets.

The Artemis team brings experience from institutions including Goldman Sachs, JPMorgan and Mesoamerica, combining investment and capital-markets expertise with sector operating experience and an understanding of the scientific and regulatory environments in which its portfolio companies operate.

Artemis applies its Five Pillars of Impact framework across its investment activities: compassionate medical access, solutions to the opioid crisis, social justice, health and wellness, and regenerative cultivation.

SOURCE Artemis Growth Partners

Share this article